Xin-Ru Pan-Zhou

Goldfinch Bio (United States) — United States

Medicine · Health Sciences

7h-index345citations19works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS drug development and treatment(5), Renal Diseases and Glomerulopathies(4), Hepatitis C virus research(3), Renal and related cancers(3), Chronic Kidney Disease and Diabetes(2)

Publications19 total

Transplanted organoids empower human preclinical assessment of drug candidate for the clinic
Science Advances·2022· 25 citedOpen Access
Discovery and Optimization of Highly Selective Inhibitors of CDK5
Journal of Medicinal Chemistry·2022· 24 citedOpen Access
Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design
Kidney International Reports·2021· 36 citedOpen Access
GFB-887, a TRPC5 Inhibitor, Is Safe and Well Tolerated and Engages the TRPC5 Target, Leading to Reductions in Urinary Rac1 in Healthy Subjects
Journal of the American Society of Nephrology·2020· 1 cited
SO038A TRANSLATIONAL KIDNEY ORGANOID SYSTEM BOLSTERS HUMAN RELEVANCE OF CLINICAL DEVELOPMENT CANDIDATE
Nephrology Dialysis Transplantation·2020
A translational kidney organoid system bolsters human relevance of clinical development candidate
2019· 2 citedOpen Access
Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis Model
ACS Medicinal Chemistry Letters·2019· 58 citedOpen Access
SUN-190 GFB-887, a small molecule inhibitor of TRPC5, protects against podocyte injury and attenuates proteinuria in models of FSGS
Kidney International Reports·2019· 5 citedOpen Access
Semi-quantitation of sparsentan circulating metabolites in focal segmental glomerulosclerosis (FSGS) patients using radioactivity/mass spectrometry peak area response factor analysis
Drug Metabolism and Pharmacokinetics·2018
SP124IN VITRO EVALUATION OF INDUCTION OF CYTOCHROME P450 ENZYMES BY SPARSENTAN AND EFFECTS OF ITS METABOLISM BY POTENTIAL
Nephrology Dialysis Transplantation·2017Open Access
Pharmacokinetics of IDX184, a liver-targeted oral prodrug of 2′-methylguanosine-5′-monophosphate, in the monkey and formulation optimization for human exposure
European Journal of Drug Metabolism and Pharmacokinetics·2015· 5 cited
P1244 FAVORABLE PRECLINICAL PROFILE OF IDX21437, A NOVEL URIDINE NUCLEOTIDE PRODRUG, FOR USE IN A DIRECT-ACTING ANTIVIRAL (DAA) REGIMEN FOR HCV
Journal of Hepatology·2014· 5 cited
750 PRECLINICAL PHARMACOKINETIC PROFILE OF IDX320, A NOVEL AND POTENT HCV PROTEASE INHIBITOR
Journal of Hepatology·2010· 1 cited
323 PRECLINICAL PHARMACOKINETIC AND SAFETY PROFILE OF IDX375, A NOVEL AND POTENT NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR
Journal of Hepatology·2009· 7 cited
NM 283 has potent antiviral activity against genotype 1 chronic hepatitis C virus (HCV-1) infection in the chimpanzee
Journal of Hepatology·2003· 18 cited
Differential Effects of Antiretroviral Nucleoside Analogs on Mitochondrial Function in HepG2 Cells
Antimicrobial Agents and Chemotherapy·2000· 120 citedOpen Access
Role of Human Liver P450s and Cytochrome b5 in the Reductive Metabolism of 3′-Azido-3′-deoxythymidine (AZT) to 3′-Amino-3′-deoxythymidine
Biochemical Pharmacology·1998· 34 cited
Comparative metabolism of the antiviral dimer AZT-P-ddl and the monomers zidovudine and didanosine by rat, monkey and human hepatocytes
Antiviral Research·1997
Human liver microsomal cytochrome P450 and B5 act as reductases in the reductive metabolism of 3′-azido-3′-deoxythymidine to 3′-amino-3′deoxythymidine.
Clinical Pharmacology & Therapeutics·1996· 4 cited

Frequent Co-authors

John F. Reilly(7), Mark W. Ledeboer(6), Jean-Christophe Harmange(6), Maolin Yu(5), Matthew H. Daniels(5), G. Malojcic(5), Amy Westerling-Bui(5), Peter Mündel(5), Thomas T. Tibbitts(4), Srinivasan P Venkatachalan(4), Xiaojian Zhou(3), Jean‐Pierre Sommadossi(3), Marie Coeffet-Le Gal(3), Eva M. Fast(3), Thomas W. Soare(3), Michael DeRan(3), Alyssa Fanelli(3), Sergii Kyrychenko(3), Hien G. Hoang(3), Grinal M. Corriea(3)